CORD submits premarket approval application for SC9 IOL

Issue: January 25, 2023

Fact checked byChristine Klimanskis, ELS

CORD has submitted a premarket approval application to the FDA for the Model SC9 IOL to treat patients with cataracts, according to a press release.

The lens was designed by J. Stuart Cumming, MD, FACS, FRCOphth, to provide intermediate vision superior to that of a standard monofocal IOL. It has a single-focus spherical optic and a rigid structure to locate the optic to provide intermediate vision.

FDA sign — CORD has submitted a premarket approval application to the FDA for the Model SC9 IOL to treat patients with cataracts, according to a press release.
*Source: Adobe Stock.*

The application is backed by the results of more than 300 patients who were followed for at least 1 year under an approved investigational device exemption, according to the release.

Cumming is also the designer of the Crystalens IOL, now owned by Bausch +Lomb, which was approved by the FDA in 2003.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

CORD submits premarket approval application for SC9 IOL

Related Content